Avacta Group PLC announced that all resolutions were passed at its Annual General Meeting, with overwhelming shareholder support for each proposal.
Avacta Extends Cash Runway as Clinical Pipeline Advances
Avacta Therapeutics (AIM: AVCT) has reported strong progress across its oncology pipeline in the first half of 2026, highlighting advances in both its clinical programmes and balance sheet ahead of
£9m fundraising gives Avacta extra firepower for cancer pipeline
Avacta Therapeutics plc (AIM: AVCT) has strengthened its balance sheet after completing an oversubscribed £9 million equity fundraising, with proceeds earmarked primarily for reducing outstanding convertible bond debt and supporting
Avacta showcases progress in salivary gland cancer study
Avacta Group PLC (AIM: AVCT) unveiled encouraging new clinical data for its lead oncology candidate AVA6000 (faridoxorubicin) at the ASCO 2026 annual meeting, highlighting both promising efficacy and a potentially
Arsenal vs PSG Set for Champions League Final Showdown in Budapest
European football’s biggest prize will be decided on Saturday as Premier League champions Arsenal face Ligue 1 winners Paris Saint-Germain in the UEFA Champions League final at Budapest’s Puskás Arena.
Avacta Therapeutics (AIM: AVCT) Board Director Changes
Avacta Therapeutics (AIM: AVCT) has announced a boardroom transition, with Richard Hughes to be appointed non-executive chairman following the company’s Annual General Meeting on 22 June 2026.
Amaroq documentary highlights race for Greenland’s critical minerals
In 2025, Greenland moved decisively to the centre of the conversation about Western critical mineral supply, Arctic security, and the future of the North Atlantic alliance. Amaroq sits at the
Avacta strengthens cancer treatment story with clinical advances
Avacta Group plc has reported significant progress across its pre|CISION oncology platform in its unaudited preliminary results for the year ended December 31, 2025, as the company advances multiple cancer
Avacta Therapeutics (AIM: AVCT) Pre|CISION® payload release vs approved ADCs
Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
Amaroq Ltd. (AIM: AMRQ) Upsized $70 million Revolving Credit Facility Agreement Signed
Amaroq Doubles Revolving Credit Facility to US$70 Million Upsized $70 million Revolving Credit Facility Agreement Signed
Avacta Therapeutics (AIM: AVCT) Avacta data AACR underline AVA6103 profile
Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform Presentation of additional analyses from FAP-Exd (AVA6103) study shows robust activity in PDX models with
Avacta Therapeutics (AIM: AVCT) Christina Coughlin – In Vivo 2026 Rising Leader
Avacta CEO Christina Coughlin Named as One of In Vivo’s 2026 Rising Leaders